Clinical Trials Logo

Unresectable Thymic Carcinoma clinical trials

View clinical trials related to Unresectable Thymic Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03694002 Active, not recruiting - Clinical trials for Metastatic Thymic Carcinoma

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Start date: March 20, 2019
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.

NCT ID: NCT03295227 Recruiting - Clinical trials for Unresectable Thymic Carcinoma

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Start date: December 6, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.